05.2025
In a groundbreaking project with Aarhus University, Aarhus University Hospital, Epilepsy Hospital Filadelfia, and Qmed Consulting, Cenexum Technologies, a portfolio company of Ventac Partners, has together been granted DKK 17.5M from Innovation Fund Denmark. The project, termed EPIFY, leverages the latest research in data processing for the detection of epileptic seizures. The project integrates advanced chip technology with a neural network for fast and accurate detection of epileptic seizures. For more information, see www.linkedin.com
04.2025
Orbit Genomics was selected for the MassChallenge 2025 U.S. Early-Stage Healthcare Program. Dede Willis, CEO and Co-founder says: “The energy at last week’s Boston kickoff went far beyond what I imagined. Grateful and excited for what’s next! Especially excited to be alongside an incredible group of companies – all tackling MASSive healthcare challenges with bold ideas and real impact.”
11.2024
Cenexum Technologies, a portfolio company of Ventac Partners, has received the prestigious Innofounder Grant from Innovation Fund Denmark. It will allow Cenexum to focus its effort on further progressing its cutting-edge Spiking Neural Network Technology to be used for smarter and more efficient diagnosis and treatment in epilepsy and potentially other neurological diseases.
09.2024
Orbit Genomics was awarded a $2 million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer test. This test will be the second generation of OrbiSeq-L, a simple blood test that diagnoses lung cancer in patients that have indeterminate pulmonary nodules. The added subtyping capability will substantially expand the use of our test while improving patient outcomes, further reducing the need for biopsies, and significantly reducing costs.
Direct to Phase II (D2P2) is a Small Business Innovation Research (SBIR) award that allows small businesses to move directly into Phase II of research and development without receiving a Phase I award. This is possible if the business has already completed Phase I-like feasibility studies using other funding sources.
Dede Willis, CEO, says: “the grant review process featured an exceptionally rigorous peer reviewed evaluation of our technology platform by experts internal and external to NIH/NCI, providing robust validation of our scientific and business approach and its potential to drive innovation in the field.”
06.2024
Rancho Santa Fe Bio, Inc., a clinical stage, cardiovascular company with technology from Sanofi and Mayo was acquired in June 2024 by former employees of Myocardia through their company EnCarda, inc. (now called Kardigan Bio).
02.2024
Orbit Genomics, a Ventac Partners portfolio company, has been selected for the inaugural cohort of startups of the CancerX Accelerator program. For more information: https://orbitgenomics.com/2024/02/26/orbit-genomics-has-been-selected-for-the-inaugural-cohort-of-startups-in-cancerxs-accelerator-program/
12.2023
Ventac Partners portfolio company Orbit Genomics (www.orbitgenomics.com) is named A Deep Tech Pioneer by Hello Tomorrow. Out of an astonishing 4,500 applications from 120 countries, Orbit Genomics stood out as one of the most promising in the realm of deep tech. This prestigious recognition signifies a significant milestone in Orbit Genomics journey to transforming complex disease diagnosis, treatment, and prevention through early warning genomics. Orbit Genomics first target is early detection of lung cancer. For further information click here.
02.2023
We are very happy to see Ventac portfolio company Regenesance BV (dba Complement Pharma BV) publish a research article with Alexion, AstraZeneca Rare Disease in the J. of Innate Immunity. The paper describes the development and validation of a new humanized C6 monoclonal antibody that inhibits assembly of the membrane attack complex (MAC): a key part of the innate immune system. The antibody has potential to treat neuronal disease by preventing MAC formation and disease progression.
Research article: https://www.karger.com/Article/Pdf/524587
02.2023
We are delighted to see our portfolio company, RORA Biologics complete its exclusive license agreement with Case Western Reserve University (Cleveland, Ohio, USA) for cancer and HIV therapy technologies developed by its Chief Scientific Officer Dr. Rafick Sékaly. RORA-Bio is using this technology to develop potential treatments for certain cancers and people living with HIV.
01.2023
RhoVac has completed the acquisition of Chosa ApS in a reversed merger transaction, see enclosed press release.